A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Incyte Corporation
Massive Bio, Inc.
Incyte Corporation
Incyte Corporation
European Organisation for Research and Treatment of Cancer - EORTC
Novartis
INSYS Therapeutics Inc